

Express Mail Label No.

EV34006426845

Dated: 10-17-03

Customer No.: 07278

Docket No.: 02313/100F138-US2

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Te Piao KING

Serial No.: T.B.A.

Art Unit: T.B.A.

Filed: Concurrently Herewith

Examiner: T.B.A.

For: **CLONING AND RECOMBINANT PRODUCTION OF POLISTINAE VENOM
ENZYMES, SUCH AS PHOSPHOLIPASE AND HYALURONIDASE, AND
IMMUNOLOGICAL THERAPIES BASED THEREON**

October 17, 2003

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Pursuant to 37 CFR 1.56, 1.97 and 1.98, the attention of the Patent and Trademark Office is hereby directed to the references listed on the attached PTO/SB/08. Copies of the listed references were either previously cited by or submitted to the USPTO in prior applications serial no. 09/806,658, filed March 30, 2001, and/or serial no. 09/166,205, filed October 1, 1998, which are relied upon by the present application for an earlier filing date under 35 U.S.C. § 120. Accordingly, the listed references are available in the file of one or both of these prior applications and they need not be re-submitted to be considered the present application.

Also enclosed herewith is an international search report that was issued in international application no. PCT/US99/23211, which is a counterpart to the present application. Certain of the references listed on the enclosed PTO/SB/08 were cited in the aforementioned international search report.

In accordance with MPEP Sections 609 and 707.05(b), it is requested that each document cited (including any cited in applicant's specification which is not repeated on the attached PTO/SB/08 be given thorough consideration and that it be cited of record in the

prosecution history of the present application by initialing on PTO/SB/08 . Such initialing is requested even if the Examiner does not consider a cited document to be sufficiently pertinent to use in a rejection, or otherwise does not consider it to be prior art for any reason, or even if the Examiner does not believe that the guidelines for citation have been fully complied with. This is requested so that each document becomes listed on the face of the patent issuing on the present application.

The present Information Disclosure Statement is being submitted in compliance with 37 CFR 1.56 insofar as an Examiner might consider any of the cited documents important in deciding whether to allow the application to issue as a patent, but the citation of each document is not to be construed as an admission that such document is necessarily relevant or prior art. No representation is intended that the cited documents represent the results of a complete search, and it is anticipated that the Examiner, in the normal course of examination, will make an independent search and will determine the best prior art consistent with 37 CFR 1.104(a) and 1.106(b) and, in the course of each search, will review for relevance every document cited on the attached form even if not initialed.

The Commissioner is authorized to charge any deficiency of up to \$300.00 or credit any excess in this fee to Deposit Account No. 04-0100.

Early and favorable consideration is earnestly solicited.

Respectfully submitted,



Mitchell Bernstein, Ph.D.
Registration No. 46,550
Agent for Applicant(s)

DARBY & DARBY P.C.
Post Office Box 5257
New York, N.Y. 10022
(212) 527-7700

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO			Complete if Known		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)			Application Number	Not Yet Assigned	
			Filing Date	Concurrently Herewith	
			First Named Inventor	Te P. King	
			Art Unit	N/A	
			Examiner Name	Not Yet Assigned	
Sheet	1	of	1	Attorney Docket Number	02313/100F138-US2

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	1.	5,593,877	01-14-2003	King	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
	2.	WO9420623	09-15-1994			
	3.	WO9400137	01-06-1994			

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	4.	FROHMAN, M.A. et al.; "Rapid Production of Full-Length cDNAs From Rare Transcripts: Amplification Using a Single Gene-Specific Oligonucleotide Primer"; Proceedings of the National Academy of Sciences of USA, US, National Academy of Science. Washington, Vol. 85, 1998, pps. 8998-9002.	
	5.	KORDIS, D. and GUBENSEK, F.; "Ammodoxytoxin C Gene Helps to Elucidate the Irregular Structure of Crotaline Group II Phospholipase A2 Genes"; <u>European Journal of Biochemistry</u> , Vol. 240, No. 1, Aug., 1996, pps. 83-90	
	6.	KING, T.P. et al.; "Yellow Jacket Venom Allergens, Hyaluronidase and Phospholipase: Sequence Similarity and Antigenic Cross-Reactivity With Their Hornet and Wasp Homologs and Possible Implications for Clinical Allergy"; <u>J. Allergy Clin. Immunol.</u> , Vol. 98, No. 3, 1996, pps. 588-600	
	7.	MUELLER, U. et al.; "Successful Immunotherapy With T-Cell Epitopes of Bee Venom Phospholipase A2 (PLA) in Patients With Bee Venom (BV) Allergy"; <u>Journal of Allergy and Clinical Immunology</u> , US, Mosby-Yearly Book, Inc., Vol. 97, No. 1, Part 03, Jan. 1996, pg. 426	
	8.	SOLDATOVA, L. et al.; "Sequence Similarity of a Hornet (D. Maculata) Venom Allergen Phospholipase A1 With Mammalian Lipases"; <u>Febs Letters</u> , Vol. 320, 1993, pps. 145-149	
	9.	LU, G. et al.; "Sequence Identity and Antigenic Cross-Reactivity of White Face Hornet Venom Allergen, Aldo a Hyaluronidase, With Other Proteins"; <u>Journal of Biological Chemistry</u> , Vol. 270, No. 9, 1995, pps. 4457-4465.	
	10.	HOFFMAN, D.R.; "Allergens in Hymenoptera Venom. XXVI: The Complete Amino Acid Sequence of Two Vespidae Venom Phospholipases"; <u>International Archives of Allergy and Immunology</u> , Vol. 104, 1994, pps. 184-190	
	11.	KING, T.P. et al.; "Murine T and B Cell Responses to Natural and Recombinant Hornet Venom Allergen Dol M 5.02 and its Recombinant Fragments"; <u>Journal of Immunology</u> , US, The Williams and Wilkins Co., Baltimore, Vol. 154, No. 2, 1995, pps. 577-584	
	12.	FORSDYKE, R.; "Conservation of Stem-Loop Potential in Introns of Snake Venom Phospholipase A2 Genes: An Application of FORS-D Analysis"; <u>Molecular Biology and Evolution</u> , Vol. 12, No. 6, 6 November 1995, pps. 1157-1165	

{W:023 131100f	Date Considered
-------------------	--------------------

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Application Number	Not Yet Assigned
				Filing Date	Concurrently Herewith
				First Named Inventor	Te P. King
				Art Unit	N/A
				Examiner Name	Not Yet Assigned
Sheet	2	of	1	Attorney Docket Number	02313/100F138-US2

13.	JUSTESEN, A. et al.; "Analysis of Two Incompletely Spliced Arabidopsis cDNA Encoding Novel Types of Peroxidase"; <u>Biochimica and Biophysica Acta</u> , Vol. 1443, 26 October 1998, pps. 149-154	
14.	DATABASE EMBL NUCLEOTIDE AND PROTEIN SEQUENCES, 7 September 1999, Hinxton, GB, AC=AF174528. <u>Polistes annularis hyaluronidase precursor mRNA, partial cds. Abstract</u>	
15.	KING, T.P. et al.; "Wasp Venom Proteins: Phospholipase A1 and B1"; <u>Archives of Biochemistry and Biophysics</u> ; 1984, Vol. 230. No. 1, pages 1-12.	
16.	SUGGS, et al. PNAS, USA, 78(11):6613-6617, 1981	
17.	EDMAN, et al. Eur. J. Biochem., 1:80-91, 1967	
18.	KING, et al., Archives of Biochem. Biophys., 230(1):1-12, 1984	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

W:\023 13\100f		Date Considered	
-------------------	--	--------------------	--